Paul J Goodfellow

List of Publications by Year
in descending order

Version: 2024-02-01

163	11,975	34105 52	29157 104
papers	citations	h-index	g-index

164	164	164	16091
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Human Molecular Genetics, 1993, 2, 851-856.	2.9	1,223
2	Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature, 2010, 464, 999-1005.	27.8	1,077
3	DICER1 Mutations in Familial Pleuropulmonary Blastoma. Science, 2009, 325, 965-965.	12.6	588
4	Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer. JAMA Oncology, 2017, 3, 464.	7.1	510
5	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	21.4	289
6	A Familial Syndrome of Pancreatic Cancer and Melanoma with a Mutation in theCDKN2Tumor-Suppressor Gene. New England Journal of Medicine, 1995, 333, 975-977.	27.0	283
7	A common variant at the TERT-CLPTM1L locus is associated with estrogen receptorâ€“negative breast cancer. Nature Genetics, 2011, 43, 1210-1214.	21.4	279
8	Epigenetic Repression of microRNA-129-2 Leads to Overexpression of SOX4 Oncogene in Endometrial Cancer. Cancer Research, 2009, 69, 9038-9046.	0.9	262
9	Use of mutation profiles to refine the classification of endometrial carcinomas. Journal of Pathology, 2012, 228, 20-30.	4.5	261
10	The T-box transcription factor gene TBX22 is mutated in X-linked cleft palate and ankyloglossia. Nature Genetics, 2001, 29, 179-183.	21.4	245
11	Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles. Modern Pathology, 2014, 27, 128-134.	5.5	218
12	Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 5908-5913.	7.1	216
13	Microsatellite Instability and Epigenetic Inactivation of MLH1 and Outcome of Patients With Endometrial Carcinomas of the Endometrioid Type. Journal of Clinical Oncology, 2007, 25, 2042-2048.	1.6	186
14	ColoSeq Provides Comprehensive Lynch and Polyposis Syndrome Mutational Analysis Using Massively Parallel Sequencing. Journal of Molecular Diagnostics, 2012, 14, 357-366.	2.8	179
15	Lymphovascular space invasion is an independent risk factor for nodal disease and poor outcomes in endometrioid endometrial cancer. Gynecologic Oncology, 2012, 124, 31-35.	1.4	169
16	Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study. Journal of Clinical Oncology, 2015, 33, 4301-4308.	1.6	163
17	FGFR2 Point Mutations in 466 Endometrioid Endometrial Tumors: Relationship with MSI, KRAS, PIK3CA, CTNNB1 Mutations and Clinicopathological Features. PLoS ONE, 2012, 7, e30801.	2.5	150
18	Identification of a Novel <emph type="ital">TP53</emph> Cancer Susceptibility Mutation Through Whole-Genome Sequencing of a Patient With Therapy-Related AML. JAMA - Journal of the American Medical Association, 2011, 305, 1568.	7.4	146

#	Article	IF	Citations
19	Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. Carcinogenesis, 2014, 35, 1012-1019.	2.8	145
20	Polymerase É› (<scp>POLE</scp>) mutations in endometrial cancer: Clinical outcomes and implications for <scp>L</scp>ynch syndrome testing. Cancer, 2015, 121, 386-394.	4.1	142
21	Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. Journal of Clinical Oncology, 2016, 34, 3062-3068.	1.6	141
22	Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer. JAMA Oncology, 2018, 4, 806.	7.1	136
23	Inhibition of Activated Fibroblast Growth Factor Receptor 2 in Endometrial Cancer Cells Induces Cell Death Despite PTEN Abrogation. Cancer Research, 2008, 68, 6902-6907.	0.9	134
24	Endometrial cancer: Molecular markers and management of advanced stage disease. Gynecologic Oncology, 2018, 150, 569-580.	1.4	133
25	Temporal order of RNase IIIb and loss-of-function mutations during development determines phenotype in DICER1 syndrome: a unique variant of the two-hit tumor suppression model. F1000Research, 2015, 4, 214.	1.6	125
26	The pseudoautosomal boundary in man is defined by an Alu repeat sequence inserted on the Y chromosome. Nature, 1989, 337, 81-84.	27.8	120
27	Clinical significance of microsatellite instability in endometrial carcinoma. Cancer, 2000, 89, 1758-1764.	4.1	117
28	BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma. Cancer, 2013, 119, 332-338.	4.1	99
29	Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target. Oncogene, 2017, 36, 168-181.	5.9	99
30	Mutational analysis ofMLH1 andMSH2 in 25 prospectively-acquired RER+ endometrial cancers. Genes Chromosomes and Cancer, 1997, 18, 219-227.	2.8	98
31	An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer. Gynecologic Oncology, 2018, 148, 174-180.	1.4	83
32	A Drosophila Model of Multiple Endocrine Neoplasia Type 2. Genetics, 2005, 171, 1057-1081.	2.9	82
33	A phase II trial of brivanib in recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study. Gynecologic Oncology, 2014, 135, 38-43.	1.4	82
34	Frequent HOXA11 and THBS2 promoter methylation, and a methylator phenotype in endometrial adenocarcinoma. Clinical Cancer Research, 2003, 9, 2277-87.	7.0	81
35	Frequent mutations ofCDKN2 in primary pancreatic adenocarcinomas. Genes Chromosomes and Cancer, 1995, 14, 189-195.	2.8	77
36	Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival. Gynecologic Oncology, 2017, 146, 588-595.	1.4	77

#	Article	IF	Citations
37	CDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinoma. Cancer Research, 2003, 63, 2033-6.	0.9	76
38	Evidence for heritable predisposition to epigenetic silencing of MLH1. International Journal of Cancer, 2007, 120, 1684-1688.	5.1	75
39	Estrogen receptor-alpha as a predictive biomarker in endometrioid endometrial cancer. Gynecologic Oncology, 2016, 141, 312-317.	1.4	75
40	Rapid cloning and characterization of new chromosome 10 DNA markers by Alu element-mediated PCR. Genomics, 1990, 7, 614-620.	2.9	74
41	Germline mutations in the multiple endocrine neoplasia type 1 gene: Evidence for frequent splicing defects. Human Mutation, 1999, 13, 175-185.	2.5	73
42	Somatic mutation profiles of clear cell endometrial tumors revealed by whole exome and targeted gene sequencing. Cancer, 2017, 123, 3261-3268.	4.1	72
43	ATR Mutation in Endometrioid Endometrial Cancer Is Associated With Poor Clinical Outcomes. Journal of Clinical Oncology, 2009, 27, 3091-3096.	1.6	71
44	Intra-tumor heterogeneity of MLH1 promoter methylation revealed by deep single molecule bisulfite sequencing. Nucleic Acids Research, 2009, 37, 4603-4612.	14.5	70
45	A specific CpG methylation pattern of theMGMT promoter region associated with reduced MGMT expression in primary colorectal cancers. Molecular Carcinogenesis, 1999, 24, 90-98.	2.7	66
46	Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data metaâ€analysis. Cancer, 2021, 127, 2409-2422.	4.1	62
47	Penetrance and Expressivity of MSH6 Germline Mutations in Seven Kindreds Not Ascertained by Family History. American Journal of Human Genetics, 2004, 74, 1262-1269.	6.2	61
48	Allelotype of follicular thyroid carcinomas reveals genetic instability consistent with frequent nondisjunctional chromosomal loss. Genes Chromosomes and Cancer, 1997, 19, 43-51.	2.8	58
49	DNA mismatch repair and TP53 defects are early events in uterine carcinosarcoma tumorigenesis. Modern Pathology, 2006, 19, 1333-1338.	5.5	58
50	Frequent mutations in the RPL22 gene and its clinical and functional implications. Gynecologic Oncology, 2013, 128, 470-474.	1.4	58
51	Mapping the limits of the human pseudoautosomal region and a candidate sequence for the male-determining gene. Nature, 1987, 328, 273-275.	27.8	56
52	Regional assignment of the human uroporphyrinogen III synthase (UROS) gene to chromosome 10q25.2?q26.3. Human Genetics, 1991, 87, 18-22.	3.8	56
53	Body mass index: Relationship to clinical, pathologic and features of microsatellite instability in endometrial cancer. Gynecologic Oncology, 2007, 104, 535-539.	1.4	54
54	PTENMutations in Endometrial Cancers with 10q LOH: Additional Evidence for the Involvement of Multiple Tumor Suppressors. Gynecologic Oncology, 1998, 71, 391-395.	1.4	53

#	Article	IF	Citations
55	Comparative DNA methylome analysis of endometrial carcinoma reveals complex and distinct deregulation of cancer promoters and enhancers. BMC Genomics, 2014, 15, 868.	2.8	49
56	Hypermethylation of miR-203 in endometrial carcinomas. Gynecologic Oncology, 2014, 133, 340-345.	1.4	49
57	Novel germline RET proto-oncogene mutations associated with medullary thyroid carcinoma (MTC): mutation analysis in Japanese patients with MTC. Oncogene, 1997, 14, 3103-3106.	5.9	48
58	The genomic organisation of the human pseudoautosomal gene MIC2 and the detection of a related locus. Human Molecular Genetics, 1993, 2, 417-422.	2.9	47
59	Mutations inMLH1 are more frequent than inMSH2 in sporadic colorectal cancers with microsatellite instability. Genes Chromosomes and Cancer, 1997, 18, 42-49.	2.8	47
60	Increased Risk for Hereditary Nonpolyposis Colorectal Cancer-Associated Synchronous and Metachronous Malignancies in Patients with Microsatellite Instability-Positive Endometrial Carcinoma Lacking MLH1 Promoter Methylation. Clinical Cancer Research, 2004, 10, 481-490.	7.0	45
61	FGFR2 mutations are rare across histologic subtypes of ovarian cancer. Gynecologic Oncology, 2010, 117, 125-129.	1.4	45
62	Differences in patterns ofTP53 andKRAS2 mutations in a large series of endometrial carcinomas with or without microsatellite instability. , 1999, 85, 119-126.		44
63	Two maternally derived missense mutations in the tyrosine kinase domain of the RET protooncogene in a patient with de novo MEN 2B. Human Molecular Genetics, 1995, 4, 1987-1988.	2.9	41
64	Antisense transcripts at the EMX2 locus in human and mouseâˆ†â€ Sequence data from this article have been deposited with the GenBank Data Library under Accession Nos. AY117034, AY117413, AY117414, and AY117415.. Genomics, 2003, 81, 58-66.	2.9	41
65	MSI in endometrial carcinoma: Absence of MLH1 promoter methylation is associated with increased familial risk for cancers. International Journal of Cancer, 2002, 99, 697-704.	5.1	40
66	FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology, 2017, 145, 366-373.	1.4	40
67	Aberrant Methylation of the X-Linked Ribosomal S6 Kinase RPS6KA6 (RSK4) in Endometrial Cancers. Clinical Cancer Research, 2011, 17, 2120-2129.	7.0	39
68	Integrative analysis identifies targetable CREB1/FoxA1 transcriptional co-regulation as a predictor of prostate cancer recurrence. Nucleic Acids Research, 2016, 44, 4105-4122.	14.5	38
69	Prognostic Significance of POLE Exonuclease Domain Mutations in High-Grade Endometrioid Endometrial Cancer on Survival and Recurrence: A Subanalysis. International Journal of Gynecological Cancer, 2016, 26, 933-938.	2.5	38
70	IGSF4 promoter methylation and expression silencing in human cervical cancer. Gynecologic Oncology, 2005, 96, 150-158.	1.4	37
71	Promoter hypermethylation of CIDEA, HAAO and RXFP3 associated with microsatellite instability in endometrial carcinomas. Gynecologic Oncology, 2010, 117, 239-247.	1.4	37
72	Promoter Hypomethylation of EpCAM-Regulated Bone Morphogenetic Protein Gene Family in Recurrent Endometrial Cancer. Clinical Cancer Research, 2013, 19, 6272-6285.	7.0	37

#	Article	IF	Citations
73	Patterns ofCTCFandZFHX3Mutation and Associated Outcomes in Endometrial Cancer. Journal of the National Cancer Institute, 2015, 107, djv249.	6.3	37
74	CMS: A Web-Based System for Visualization and Analysis of Genome-Wide Methylation Data of Human Cancers. PLoS ONE, 2013, 8, e60980.	2.5	36
75	Frequent PIK3CA Mutations in Colorectal and Endometrial Tumors With 2 or More Somatic Mutations in Mismatch Repair Genes. Gastroenterology, 2016, 151, 440-447.e1.	1.3	36
76	Methylation and mutational analysis of p27^{kip1} in prostate carcinoma. Prostate, 2001, 48, 248-253.	2.3	35
77	Mismatch repair protein expression in 1049 endometrial carcinomas, associations with body mass index, and other clinicopathologic variables. Gynecologic Oncology, 2014, 133, 43-47.	1.4	35
78	Mismatch repair deficiency identifies patients with highâ€intermediateâ€“risk (HIR) endometrioid endometrial cancer at the highest risk of recurrence: A prognostic biomarker. Cancer, 2019, 125, 398-405.	4.1	35
79	Reduced Survival in Patients With Ductal Pancreatic Adenocarcinoma Associated With CDKN2 Mutation. Journal of the National Cancer Institute, 1996, 88, 680-682.	6.3	34
80	DNA Repair Pathway Profiling and Microsatellite Instability in Colorectal Cancer. Clinical Cancer Research, 2006, 12, 5104-5111.	7.0	34
81	Differential Methylation Hybridization Array of Endometrial Cancers Reveals Two Novel Cancer-Specific Methylation Markers. Clinical Cancer Research, 2007, 13, 2882-2889.	7.0	34
82	Characterization of the Homeodomain Gene EMX2: Sequence Conservation, Expression Analysis, and a Search for Mutations in Endometrial Cancers. Genomics, 2001, 76, 37-44.	2.9	33
83	Rare BRIP1 Missense Alleles Confer Risk for Ovarian and Breast Cancer. Cancer Research, 2020, 80, 857-867.	0.9	33
84	Expression Profiling of Mouse Endometrial Cancers Microdissected from Ethanol-Fixed, Paraffin-Embedded Tissues. American Journal of Pathology, 2003, 162, 755-762.	3.8	32
85	RAS/RAF mutation and defective DNA mismatch repair in endometrial cancers. American Journal of Obstetrics and Gynecology, 2004, 190, 935-939.	1.3	32
86	Prospective Statewide Study of Universal Screening for Hereditary Colorectal Cancer: The Ohio Colorectal Cancer Prevention Initiative. JCO Precision Oncology, 2021, 5, 779-791.	3.0	31
87	Evaluation of the family history collection process and the accuracy of cancer reporting among a series of women with endometrial cancer. Clinical Cancer Research, 2002, 8, 1849-56.	7.0	31
88	Phosphatase and tensin homolog (PTEN) pseudogene expression in endometrial cancer: a conserved regulatory mechanism important in tumorigenesis?. Gynecologic Oncology, 2012, 124, 340-346.	1.4	30
89	Noncatalytic PTEN missense mutation predisposes to organ-selective cancer development in vivo. Genes and Development, 2015, 29, 1707-1720.	5.9	29
90	The ? subunit locus of the human fibronectin receptor: DNA restriction fragment length polymorphism and linkage mapping studies. Human Genetics, 1989, 83, 383-390.	3.8	28

#	Article	IF	Citations
91	High Frequency Strand Slippage Mutations inCTCFin MSI-Positive Endometrial Cancers. Human Mutation, 2014, 35, 63-65.	2.5	28
92	Absence of PTEN Repeat Tract Mutation in Endometrial Cancers with Microsatellite Instability. Gynecologic Oncology, 2000, 79, 101-106.	1.4	27
93	The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas. Cancer, 2018, 124, 65-73.	4.1	27
94	Lower Uterine Segment Involvement is Associated with Poor Outcomes in Early-Stage Endometrioid Endometrial Carcinoma. Annals of Surgical Oncology, 2011, 18, 1419-1424.	1.5	26
95	DICER1 expression and outcomes in endometrioid endometrial adenocarcinoma. Cancer, 2011, 117, 1446-1453.	4.1	26
96	MLH3 Mutation in Endometrial Cancer. Cancer Research, 2006, 66, 7502-7508.	0.9	25
97	Evolutionary conservation of the human homologue of the yeast cell cycle control gene cdc2 and assignment of Cd2 to chromosome 10. Human Genetics, 1988, 78, 333-337.	3.8	24
98	InfrequentCDKN2 mutation in human differentiated thyroid cancers. , 1996, 15, 5-10.		24
99	Mapping an Endometrial Cancer Tumor Suppressor Gene at 10q25 and Development of a Bacterial Clone Contig for the Consensus Deletion Interval. Genomics, 1998, 52, 9-16.	2.9	24
100	Double somatic mismatch repair gene pathogenic variants as common as Lynch syndrome among endometrial cancer patients. Gynecologic Oncology, 2021, 160, 161-168.	1.4	24
101	Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials. Oncotarget, 2017, 8, 84579-84594.	1.8	23
102	Inherited cancers associated with the RET proto-oncogene. Current Opinion in Genetics and Development, 1994, 4, 446-452.	3.3	22
103	16q loss of heterozygosity and microsatellite instability in Wilms' tumor. Journal of Pediatric Surgery, 2000, 35, 891-897.	1.6	22
104	Human telomerase RNA mutations and bone marrow failure. Lancet, The, 2003, 361, 1993-1994.	13.7	22
105	The role of racial genetic admixture with endometrial cancer outcomes: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology, 2016, 140, 264-269.	1.4	22
106	Linkage analysis of X-linked cleft palate and ankyloglossia in Manitoba Mennonite and British Columbia Native kindreds. Human Genetics, 1994, 94, 141-8.	3.8	21
107	Expression mapping at 12p12-13 in advanced prostate carcinoma. International Journal of Cancer, 2004, 109, 668-672.	5.1	21
108	Frequent deletion of chromosome 1p sequences in an aggressive histologic subtype of endometrial cancer. Human Molecular Genetics, 1996, 5, 1017-1021.	2.9	20

#	Article	IF	Citations
109	Aberrantly activated pSTAT3-Ser727 in human endometrial cancer is suppressed by HO-3867, a novel STAT3 inhibitor. Gynecologic Oncology, 2014, 135, 133-141.	1.4	20
110	Low frequency ofCDKN2 mutation in endometrial carcinomas. Molecular Carcinogenesis, 1995, 13, 210-212.	2.7	19
111	Absence of MGMT promoter methylation in endometrial cancer. Gynecologic Oncology, 2009, 112, 224-228.	1.4	19
112	Novel APC promoter and exon 1B deletion and allelic silencing in three mutation-negative classic familial adenomatous polyposis families. Genome Medicine, 2015, 7, 42.	8.2	19
113	Genotypic and phenotypic progression in endometrial tumorigenesis: Determining when defects in DNA mismatch repair andKRAS2 occur. Genes Chromosomes and Cancer, 2001, 32, 295-301.	2.8	18
114	Defective DNA mismatch repair and XRCC2 mutation in uterine carcinosarcomas. Gynecologic Oncology, 2006, 100, 107-110.	1.4	18
115	Uterine Serous Carcinoma: Increased Familial Risk for Lynch-Associated Malignancies. Cancer Prevention Research, 2012, 5, 435-443.	1.5	18
116	Glycogen Synthase Kinase 3Î² Inhibition as a Therapeutic Approach in the Treatment of Endometrial Cancer. International Journal of Molecular Sciences, 2013, 14, 16617-16637.	4.1	18
117	Identification of endometrial cancer methylation features using combined methylation analysis methods. PLoS ONE, 2017, 12, e0173242.	2.5	18
118	STAT3/PIAS3 Levels Serve as â€œEarly Signatureâ€•Genes in the Development of High-Grade Serous Carcinoma from the Fallopian Tube. Cancer Research, 2018, 78, 1739-1750.	0.9	18
119	Identification and characterization of a gene at D10S94 in the MEN2A region. Genomics, 1992, 13, 344-348.	2.9	16
120	Mutational Analysis of the PMS2 Gene in Sporadic Endometrial Cancers with Microsatellite Instability. Gynecologic Oncology, 1999, 74, 395-399.	1.4	16
121	Excess of early onset multiple myeloma in endometrial cancer probands and their relatives suggests common susceptibility. Gynecologic Oncology, 2007, 105, 390-394.	1.4	16
122	Epitope-positive truncating MLH1 mutation and loss of PMS2: implications for IHC-directed genetic testing for lynch syndrome. Familial Cancer, 2009, 8, 501-504.	1.9	16
123	The MLH1 â^'93 promoter variant influences gene expression. Cancer Epidemiology, 2010, 34, 93-95.	1.9	16
124	Adipokines Deregulate Cellular Communication via Epigenetic Repression of Gap Junction Loci in Obese Endometrial Cancer. Cancer Research, 2019, 79, 196-208.	0.9	16
125	Reduced DICER1 Elicits an Interferon Response in Endometrial Cancer Cells. Molecular Cancer Research, 2012, 10, 316-325.	3.4	15
126	NovelSOX17frameshift mutations in endometrial cancer are functionally distinct from recurrent missense mutations. Oncotarget, 2017, 8, 68758-68768.	1.8	15

#	Article	IF	Citations
127	Up-Front Multigene Panel Testing for Cancer Susceptibility in Patients With Newly Diagnosed Endometrial Cancer: A Multicenter Prospective Study. JCO Precision Oncology, 2021, 5, 1588-1602.	3.0	15
128	A cluster of CpG islands at D10S94, near the locus responsible for multiple endocrine neoplasia type 2A (MEN2A). Genomics, 1992, 13, 339-343.	2.9	14
129	Low Allele Frequency of MLH1 D132H in American Colorectal and Endometrial Cancer Patients. Diseases of the Colon and Rectum, 2005, 48, 1723-1727.	1.3	14
130	Physical and Genetic Maps for Chromosome 10. Genomics, 1993, 16, 320-324.	2.9	13
131	A high-resolution meiotic mapping panel for the pericentromeric region of chromosome 10. Genomics, 1992, 13, 607-612.	2.9	12
132	A new HLAâ€ÐRB1 allele formed by an intraâ€exonic interallelic crossover. Tissue Antigens, 1993, 42, 141-143.	1.0	12
133	A 1-Mb Bacterial Clone Contig Spanning the Endometrial Cancer Deletion Region at 1p32â€“p33. Genomics, 1999, 57, 62-69.	2.9	12
134	The mutational spectrum of FOXA2 in endometrioid endometrial cancer points to a tumor suppressor role. Gynecologic Oncology, 2016, 143, 398-405.	1.4	12
135	Linkage analysis of multiple endocrine neoplasia type 2A (MEN-2A) and three DNA markers on chromosome 20: Evidence against synteny. Cancer Genetics and Cytogenetics, 1987, 27, 327-334.	1.0	11
136	Human repeat element-mediated PCR: Cloning and mapping of chromosome 10 DNA markers. Genomics, 1992, 13, 409-414.	2.9	10
137	Genomic and Yeast Artificial Chromosome Long-Range Regular Article Linking Six Loci in 10q11.2 and Spanning the Multiple Endocrine Neoplasia Type 2A (MEN2A) Region. Genomics, 1993, 17, 611-617.	2.9	10
138	Diethylstilbestrol effects and lymphomagenesis in Mlh1 â€deficient mice. International Journal of Cancer, 2005, 115, 666-669.	5.1	10
139	Transcriptional profiling endometrial carcinomas microdissected from DES-treated mice identifies changes in gene expression associated with estrogenic tumor promotion. International Journal of Cancer, 2006, 119, 1843-1849.	5.1	10
140	Dicer1 Phosphomimetic Promotes Tumor Progression and Dissemination. Cancer Research, 2019, 79, 2662-2668.	0.9	10
141	Infrequent methylation of the DUSP6 phosphatase in endometrial cancer. Gynecologic Oncology, 2010, 119, 146-150.	1.4	9
142	Assessing the prognostic role of ATR mutation in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology, 2015, 138, 614-619.	1.4	9
143	MAX Mutations in Endometrial Cancer: Clinicopathologic Associations and Recurrent MAX p.His28Arg Functional Characterization. Journal of the National Cancer Institute, 2018, 110, 517-526.	6.3	9
144	Atypical Clustering of Gynecologic Malignancies: A Family Study Including Molecular Analysis of Candidate Genes. Gynecologic Oncology, 2000, 77, 18-25.	1.4	8

#	Article	IF	Citations
145	A Human Yeast Artificial Chromosome Containing the Multiple Endocrine Neoplasia Type 2B Ret Mutation Does Not Induce Medullary Thyroid Carcinoma but Does Support the Growth of Kidneys and Partially Rescues Enteric Nervous System Development in Ret-Deficient Mice. American Journal of Pathology, 2005, 166, 265-274.	3.8	8
146	Novel MicroRNAs regulating proliferation and apoptosis in uterine papillary serous carcinomas. Cancer Letters, 2013, 335, 314-322.	7.2	8
147	Primum non nocere : Are we ready for POLE testing in endometrial cancer?. Gynecologic Oncology, 2017, 147, 240-242.	1.4	7
148	Evaluating the efficacy of enzalutamide and the development of resistance in a preclinical mouse model of type-I endometrial carcinoma. Neoplasia, 2020, 22, 484-496.	5.3	7
149	Endometrial Cancer: Who Lives, Who Dies, Can We Improve Their Story?. Oncologist, 2021, 26, 1044-1051.	3.7	7
150	MonoSeq Variant Caller Reveals Novel Mononucleotide Run Indel Mutations in Tumors with Defective DNA Mismatch Repair. Human Mutation, 2016, 37, 1004-1012.	2.5	6
151	Functional characterization of recurrent FOXA2 mutations seen in endometrial cancers. International Journal of Cancer, 2018, 143, 2955-2961.	5.1	6
152	GOG 8020/210: Risk stratification of lymph node metastasis, disease progression and survival using single nucleotide polymorphisms in endometrial cancer: An NRG oncology/gynecologic oncology group study. Gynecologic Oncology, 2019, 153, 335-342.	1.4	6
153	Loss of Heterozygosity of Chromosome 3p Sequences Is an Infrequent Event in Endometrial Cancer. Gynecologic Oncology, 1996, 60, 308-312.	1.4	5
154	Dinucleotide Repeat in the third Intron of the Fabp3Imdgi Putative Tumor Suppressor Gene. Disease Markers, 1996, 13, 57-59.	1.3	5
155	Germline mutations in the multiple endocrine neoplasia type 1 gene: Evidence for frequent splicing defects. Human Mutation, 1999, 13, 175.	2.5	5
156	No evidence forBCL10 mutation in endometrial cancers with microsatellite instability. Human Mutation, 2001, 17, 117-121.	2.5	4
157	Clustering of Lynch syndrome malignancies with no evidence for a role of DNA mismatch repair. Gynecologic Oncology, 2008, 108, 438-444.	1.4	4
158	PIK3CA mutations in colorectal and endometrial cancer with double somatic mismatch repair mutations compared to Lynch syndrome.. Journal of Clinical Oncology, 2015, 33, 3550-3550.	1.6	4
159	Four new mutations in the DNA mismatch repair gene MLH1 in colorectal cancers with microsatellite instability. Human Mutation, 1998, 12, 73-73.	2.5	3
160	Traditional Approaches to Molecular Genetic Analysis. Advances in Experimental Medicine and Biology, 2017, 943, 99-118.	1.6	2
161	A new polymorphic marker (D10S97) tightly linked to the multiple endocrine neoplasia type 2A (MEN2A) locus. Human Genetics, 1993, 90, 516-20.	3.8	1
162	Diverse mutational signatures in endometrial cancer: implications for tumor etiology and evolution. Gynecologic Oncology, 2019, 152, 1-2.	1.4	0

#	Article	IF	Citations
163	High prevalence of actionable germline variants in unselected endometrial cancer (EC) patients.. Journal of Clinical Oncology, 2021, 39, 5577-5577.	1.6	0